Cabaletta Bio Inc CABA

$1.41 -0.14 (-9.03%)

Valuation

Market cap
239,058,000
Revenue TTM
$0
Net income TTM
$-167,860,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
6,676,300
Avg volume
5,438,450
Day's range
$1.40 – $1.62
Shares out
169,545,000
Stochastic %K
1%
Beta
3.48
Analysts
Strong Sell
Price target
$13.25

Price

Company profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated...

Show more

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 759 3100
Website
https://www.cabalettabio.com
Address
2929 Arch Street, Suite 600, Philadelphia, United States

Latest news

Stocktwits

Moonman321 Oct 19, 4:59 AM
$CABA Small caps are getting hit by fears of more rate hikes and high oil prices—but both could turn. Oil flows through the Strait of Hormuz are already back to around 80% of pre-war levels. If that recovery continues, oil could fall fast. And with the Fed more likely to hold rates than raise them, the pressure on small caps could ease. The Russell 2000 is nearly 10% below its August high. If oil keeps coming down and rate-hike fears fade, small caps could come roaring back. This setup is about two get explosive.
0 replies
Kawasaki1 Oct 19, 3:16 AM
$CABA But why? a dollar 41?? Really?
0 replies
Adamchristlover Oct 19, 1:55 AM
$SLS $LAES $BTBT $CABA $SOFI Let us do it Jack. You are a good man but you can not fix a rigged market alone.
0 replies
jacksparo Oct 19, 1:47 AM
$SLS $LAES $BTBT $CABA $SOFI They abused our money in the last two weeks badly.. Time for the retail traders to grow some thick skin and fight back against the shorts … Let’s fight back next week ✅📈✅📈!
2 replies
Achandler787 Oct 17, 9:07 PM
$CABA
0 replies
Matthew619 Oct 17, 6:52 PM
$CABA Feels like a scam or they want your shares very badly….
3 replies
R0MER0 Oct 17, 12:09 PM
$CABA next week should be good ✍🏽
0 replies
2tacos_plis Oct 17, 6:48 AM
$CABA Called it to the T! Hey, people lie and companies lie but numbers don’t. Put that in your salad and toss it! 😂🫵🏼😂😘😘
2 replies